News for Adhera Therapeutics, Inc. (ATRX)

Data will be instrumental in upcoming Phase 2 clinical trial of MLR-1023, Adhera’s novel Type 1 Diabetes drug candidateCompany moving forward with...

Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage...

Read Trevena (NASDAQ:TRVN) & Adhera Therapeutics (OTCMKTS:ATRX) Head-To-Head Survey at ETF Daily News

Read Adhera Therapeutics, Inc. (OTCMKTS:ATRX) Short Interest Update at ETF Daily News

Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage...

Read Adhera Therapeutics, Inc. (OTCMKTS:ATRX) Sees Significant Increase in Short Interest at ETF Daily News

Read Short Interest in Adhera Therapeutics, Inc. (OTCMKTS:ATRX) Decreases By 59.5% at ETF Daily News

Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical...

Read Reviewing Adhera Therapeutics (OTCMKTS:ATRX) and Sensei Biotherapeutics (NASDAQ:SNSE) at ETF Daily News